Abstract
Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.
Original language | English (US) |
---|---|
Pages (from-to) | 872-876 |
Number of pages | 5 |
Journal | Leukemia Research |
Volume | 37 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2013 |
Keywords
- Acute myeloid leukemia
- Complete remission
- Cyclophosphamide
- Etoposide
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research